Concepedia

Author

Jacqueline McBride

Stanford UniversityORCID

Also Known As

J McBride, J. M. McBride, J. McBride, JACQUELINE McBRIDE, Jacqueline M McBride, Jacqueline M. McBride, Jacqueline M. Mcbride, Jacqueline McBride, Jacqueline M. McBride, Jeremy Lim

109

Publications

6.5K

Citations

31

H-Index

45

Concepts

All Affiliations

Stanford UniversityUniversity of California, San FranciscoRoche (Canada)Leeds Teaching Hospitals NHS TrustBaylor College of Medicine
JM

About

Jacqueline McBride is an author at Stanford University specializing in medicine, immunology, and cell biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

4K

2

Cell Biology

6

6

3.5K

3

Natural Sciences

2

2

3.1K

4

Health Sciences

1

1

51

5

Biochemistry

1

1

3K

Jacqueline McBride

×

36

Publications

6.2K

Citations

29

H-Index

YearCitations

Cryopyrin activates the inflammasome in response to toxins and ATP

Sanjeev Mariathasan, David S. Weiss, Kim Newton,

Nature

2006

3K

Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice

Janet Lau, Jeanne Cheung, Armando Navarro,

Nature Communications

2017

358

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)

Kenneth Kalunian, Joan T. Merrill, Romeo Maciuca,

Annals of the Rheumatic Diseases

2015

335

Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

David Dornan, Fiona Bennett, Yvonne Chen,

Blood

2009

263

Leukocyte functional antigen 1 lowers T cell activation thresholds and signaling through cytohesin-1 and Jun-activating binding protein 1

Omar D. Perez, Dennis J. Mitchell, Gina C. Jager,

Nature Immunology

2003

211

Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor

Rong Deng, Daniela Bumbaca, Cinthia V. Pastuskovas,

mAbs

2016

196

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo‐controlled, double‐blind, dose‐escalation study

Jacqueline McBride, Jenny Jiang, Alexander R. Abbas,

Arthritis & Rheumatism

2012

183

Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE

William P. Kennedy, Romeo Maciuca, Kristen Wolslegel,

Lupus Science & Medicine

2015

150

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade

Romain Banchereau, Avantika S. Chitre, Alexis Scherl,

Journal for ImmunoTherapy of Cancer

2021

143

IL-10 alters DC function via modulation of cell surface molecules resulting in impaired T-cell responses

Jacqueline McBride, Thomas Jung, J E de Vries,

Cellular Immunology

2002

114

Page 1